Bispecific molecules cross-linking ITIM and ITAM for therapy
US7118743B2 · kind B2 · utility
8Cited by
9References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 16, 2001 |
| Grant date | Oct 10, 2006 |
| Priority date | — |
| Expiry date | Mar 16, 2021 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention includes bispecific molecules capable of cross-linking ITAM and ITIM receptors on a cell in order to inhibit cell activation, as well as gene therapy approaches using nucleotides encoding such bispecific molecules for expression in vivo. One example of an ITAM/ITIM receptor pair is FcεRI and HM18, and another is FcεRI and FcγRII. Cross-linking of these receptors with a bispecific molecule of the invention would lead to inhibition of the release of allergic mediators and amelioration of the symptoms of allergic diseases. Other diseases can be ameliorated by cross-linking ITIM/ITAM receptor pairs.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.